/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Matinas BioPharma Holdings Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.7503 -0.0719(-7.19%) MTNB at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 0.75
Highest Today 0.86
Today’s Open 0.8227
Prev. Close 0.8084
52 Week High 3.09
52 Week Low 0.47
Day’s Range: Low 0.75 High 0.86
52-Week Range: Low 0.47 High 3.09
1 day return -
1 Week return +9.15
1 month return -25.98
3 month return -49.16
6 month return +5.47
1 year return +47.0
3 year return +33.93
5 year return -21.87
10 year return -

Institutional Holdings

Market Status

Strong Buy: 0

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 5.18 M

PB Ratio 0.7438

PE Ratio 0.0

Enterprise Value 1.70 M

Total Assets 12.64 M

Volume 29619

Company Financials

Annual Revenue FY23:2159000 2.2M, FY22:3188000 3.2M, FY21:33333 0.0M, FY20:158333 0.2M, FY19:90000 0.1M

Annual Profit FY23:null 0.0M, FY22:-13490000 -13.5M, FY21:33333 0.0M, FY20:158333 0.2M, FY19:90000 0.1M

Annual Net worth FY23:-21262000 -21.3M, FY22:-13015000 -13.0M, FY21:-21173454 -21.2M, FY20:-20598962 -20.6M, FY19:-15585184 -15.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:962000 1.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-124000 -0.1M, Q1/2025:-85000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-241000 -0.2M

Quarterly Net worth Q3/2025:-2150000 -2.2M, Q2/2025:-5245000 -5.2M, Q1/2025:-1656000 -1.7M, Q3/2024:-4275000 -4.3M, Q2/2024:-5719000 -5.7M

Fund house & investment objective

Company Information Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Organisation Biotechnology

Employees 3

Industry Biotechnology

CEO Mr. Jerome D. Jabbour J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow